VVUS QNEXZ Type 2 Diabetes Cure ~ ""Given VVUS’s QNEXA's profile, QNEXA (VI-0521) could potentially emerge as a powerful new medication in the treatment of Type 2 Diabetes"". Quoted Directly From The EASD Presentation, Link Below!!!

Do Your Due Diligence LINK From The EASD Presentation...

Due Diligence ~ Read & Comprehend For Yourself Link Here:

http://www.vivus.com/images/stories/down...

Note The Last Slide:

Clinical Treatment Implications

• Observed benefits of VI-0521 exceeded Standard-of-Care
management alone in a high-risk, co-morbid, diabetic
population

• The therapeutic efficacy of VI-0521 regarding glycemic control,
weight loss, and improvements in cardiometabolic disease risk
factors are progressive and sustained at 56 weeks of therapy.

• Superior glycemic control in VI-0521-treated patients was
achieved despite a net reduction in the need for diabetic
medications.

• 4 times as many Standard-of-Care subjects required rescue .

• VI-0521 was well tolerated without associated hypoglycemia or
SAEs

• Given this profile, VI-0521 could potentially emerge as a
powerful new medication in the treatment of Type 2 Diabetes.

By, By shorts...